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ABSTRACT 64 
Risk variants of the fat-mass and obesity-associated (FTO) gene have been associated with 65 
increased obesity. However, the evidence for associations between FTO genotype and 66 
macronutrients intake has not been reviewed systematically. Our aim was to evaluate 67 
potential associations between FTO genotype and intakes of total energy, fat, carbohydrate 68 
and protein. We undertook a systematic literature search in Medline, Scopus, EMBASE and 69 
Cochrane of associations between macronutrients intake and FTO genotype in adults. Beta 70 
coefficients and confidence intervals were used for per-allele comparisons. Random-effects 71 
models assessed the pooled effect sizes. We identified 56 eligible studies reporting on 213 72 
173 adults. For each copy of the FTO risk allele, individuals reported 6.46 kcal/day (95% CI: 73 
10.76, 2.16) lower total energy intake (P=0.003). Total fat (P=0.028) and protein (P=0.006), 74 
but not carbohydrate intakes, were higher in those carrying the FTO risk allele. After 75 
adjustment for body weight, total energy intakes remained significantly lower in individuals 76 
with the FTO risk genotype (P=0.028). The FTO risk allele is associated with a lower reported 77 
total energy intake and with altered patterns of macronutrients intake. Although significant, 78 
these differences are small and further research is needed to determine whether the 79 
associations are independent of dietary misreporting.  80 
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INTRODUCTION 81 
Obesity is a major health problem worldwide with 16.6 % of European adults1 and 9.3% of 82 
adults worldwide now obese2. Obesity is due to a positive energy balance sustained over 83 
substantial time and is associated with carriage of risk variants in genes, some of which 84 
appear to influence appetite regulation3. Genome-wide association studies (GWAS) have 85 
indicated that single nucleotide polymorphisms (SNPs) in the fat mass and obesity-86 
associated gene (FTO) are strongly associated with increased body mass index (BMI) and 87 
adiposity across age groups4-6. Individuals homozygous for the risk allele of FTO (rs9939609) 88 
have a 1.7-fold increased risk of being obese compared with subjects homozygous for the 89 
lower-risk allele4.  90 
Some evidence suggests that the obesity risk attributable to polymorphisms in FTO could be 91 
modified by dietary intakes. In particular, limiting saturated fat intake seems to be 92 
associated with a lower risk of weight gain in individuals with the FTO risk allele7,8. Although 93 
the mechanism responsible for the link between carriage of the FTO risk allele, dietary 94 
intake and BMI remains unclear, evidence suggests that the FTO gene may regulate energy 95 
homeostasis9. FTO genotype appears to determine neural responses to circulating 96 
concentrations of the hunger hormone ghrelin10, which may lead to increased energy intake 97 
in those carrying the risk allele. A recent GWAS has found a robust association between FTO 98 
genotype and protein intake11 but associations between FTO genotype and intakes of 99 
macronutrients12,13 and of total energy14-16 are less consistent17. Indeed, two recent meta-100 
analyses have indicated that the FTO risk allele is associated with lower total energy intake 101 
in adults18. A critical and systematic analysis of the evidence on the associations between 102 
FTO genotype and intakes of the total energy and macronutrients is lacking. 103 
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This systematic review and meta-analysis aimed to evaluate the evidence for associations 104 
between FTO genotype (rs9939609 or a proxy) and macronutrients intake (total energy, 105 
total fats, saturated fatty acids (SFA), monounsaturated fatty acids (MUFA), polyunsaturated 106 
fatty acids (PUFA), carbohydrate and protein) in adults. 107 
 108 
METHODS AND PROCEDURES 109 
Our systematic review was conducted according to the Cochrane19 and the Centre for 110 
Reviews and Dissemination guidelines20 and is reported in line with PRISMA guidelines21 111 
(Supplementary material, Table 1). The protocol has been registered with PROSPERO, the 112 
International Prospective Register of Systematic Reviews (Registration number 113 
CRD42014010087). 114 
 115 
Search strategy 116 
Electronic searches were conducted to identify studies reporting the association between 117 
macronutrient intake (total energy, total fat, saturated, mono- and polyunsaturated fatty 118 
acids (SFA, MUFA, PUFA), carbohydrate and/or protein) and the FTO gene (rs9939609 or a 119 
proxy). The search strategy involved combining two search themes using the Boolean 120 
operator “and”. The first theme was (“FTO” OR "fat mass and obesity associated”) and the 121 
second theme was (“carbohydrate” OR “diet” OR “protein” OR “energy” OR “fat” OR 122 
“macronutrient”). OVID MEDLINE (http://www.nlm.nih.gov/bsd/pmresources.html), 123 
Embase (http://www.embase.com/), Scopus (www.scopus.com), and Cochrane 124 
(http://www.thecochranelibrary.com/view/0/index.html) were searched systematically for 125 
 
 
7 
studies published between inception and September 2014. Reference lists of identified 126 
publications and previously published related systematic reviews were hand searched to 127 
identify other studies potentially eligible for inclusion. 128 
 129 
Study selection and screening 130 
Observational studies, including cross-sectional, prospective and case-control studies and 131 
randomized trials evaluating the association between FTO and macronutrients intake were 132 
included in this review. Only English language abstracts were included. Studies in children 133 
and in animals were excluded. Two reviewers (KML and CCM) assessed titles and abstracts 134 
of all identiﬁed publications independently. When a study could not be excluded with 135 
certainty at this stage, the full-text was obtained for evaluation.  136 
 137 
Data extraction and quality assessment 138 
A standardized, pre-piloted form was used to extract data from the included studies for 139 
assessment of study quality and evidence synthesis. Data extraction and a validity 140 
assessment were carried out independently by two reviewers (KML, CCM) and any 141 
discrepancies were resolved by discussion with a third reviewer (JL). Data on participant 142 
characteristics (including ethnicity, age and sex), study designs, outcomes and exposures 143 
(FTO SNP and intakes of total energy, fat (including type of fat), carbohydrate and protein) 144 
were extracted. For the outcome data, the mean intakes or the beta coefficients for total 145 
energy (kcal/day) intake and intakes of fat, SFA, MUFA, PUFA, carbohydrate and protein (all 146 
expressed as percentage of total energy intake) per risk allele were extracted. Authors were 147 
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contacted to request missing/additional data. Cochrane Collaboration criteria were used to 148 
examine the risk of bias of each study, including completeness of outcome data and 149 
selective outcome reporting19. The FTO SNPs included in this meta-analyses have been 150 
reported to be in high linkage disequilibrium (LD)22. 151 
 152 
Statistical analysis 153 
Individual study beta coefficients were interrogated as the primary outcome for evaluation 154 
of per allele differences in macronutrients intake. In addition, where relevant data were 155 
available, energy and macronutrient intakes per kg body weight were calculated. Random-156 
effects models were used to estimate the pooled effect sizes and account for both sampling 157 
error and inter-study population variation23. Meta-estimates were weighed by the inverse of 158 
the variance of the effect size (that is, 1/variance), where variance took into account the 159 
two potential sources of variation (i.e. within-studies and between-studies variance). As 160 
suggested by Higgins et al.19 excessive weightings from “double counts” originating from the 161 
“shared” group (that is participants homozygous for the no risk allele) were controlled by 162 
splitting the sample size of the shared group into approximately equal smaller groups for 163 
the comparisons; the means and standard deviations were left unchanged. When available, 164 
we used results from multivariate models with the most complete adjustment for potential 165 
confounders as reported in the original studies. Additional subgroup analyses investigated 166 
variables including age, sex, ethnicity and BMI. All statistical analyses were conducted using 167 
Stata 13.0 software (Stata, College Station, TX, UDA). The I2 test was conducted to evaluate 168 
heterogeneity between studies24 and the 95% CI for I2 were calculated using Higgins et al.’s 169 
method25,26. Publication bias was appraised by visual inspection of funnel plots of effect size 170 
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against the standard error, with asymmetry assessed formally with Begg’s and Egger’s tests, 171 
where a P-value < 0.1 was considered as significant27. To investigate sources of 172 
heterogeneity, meta-regression was conducted using age (continuous), sex (binary), BMI 173 
(continuous), ethnicity (factor variable; African American, Asian, Spanish/Hispanic, 174 
Caucasian, Mixed) and study design (binary; intervention and observational) as covariates. 175 
 176 
Sensitivity analyses 177 
Stratified analyses were performed based on age group (binomial using the median age of 178 
participants in studies) and ethnicity (Caucasian, Asian, Spanish/Hispanic, African American 179 
or Mixed). To evaluate the validity of reported energy intake, basal metabolic rates were 180 
calculated by the Oxford equations28 and used to estimate total energy intake to basal 181 
metabolic rate ratios (EI/BMR). Under-reporting of energy intake was considered evident for 182 
EI/BMR ratios of less than 1.5529. To assess the influence of extreme values, studies where 183 
the beta coefficients for energy intake were ± 2SD from the mean were excluded. 184 
Associations between FTO and total energy and macronutrients intake were adjusted for 185 
body weight in studies where these variables were available by risk allele. Galbraith plots 186 
were used as a secondary method of detecting between study heterogeneity. Where the 187 
data were available, we assessed the effect of alcohol intake on the relationship between 188 
FTO and total energy intake, the association between food energy (kcal/day) and FTO 189 
genotype and the association between percentage of total energy intake from alcohol and 190 
FTO genotype. 191 
 192 
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RESULTS 193 
Our detailed searches identified 3 247 articles (Figure 1).  After removal of duplicates a 194 
further 1 566 articles were excluded based on their titles and 58 full text articles were 195 
reviewed. Thirty two full-text articles were excluded due to insufficient information on 196 
dietary intakes and a further 7 as they were in children only. Fifty-six studies16-18,30-44 (from 197 
26 full-text articles) were included in the meta-analysis (Table 1). Authors (n=25) were 198 
contacted for additional information, including body weight and percentage energy from 199 
alcohol, and those who provided additional information were acknowledged (n=16). 200 
 201 
Study characteristics 202 
Twenty-four studies used a population or community-based design. Six studies were cross-203 
sectional in design, 11 were case-control or nested case-control studies, 8 were intervention 204 
studies and seven were family, twin or birth cohorts. The pooled population included in this 205 
meta-analysis was 213 173 adults. The mean age (± standard deviation) was 53.0 ± 9.6 years 206 
(range 31 to 75 years) and the mean BMI was 26.6 ± 2.45 kg/m2 (range 19.4 to 36.3 kg/m2). 207 
Most studies used a Food Frequency Questionnaire (FFQ; n=40) to estimate dietary intakes, 208 
four used dietary recalls, 8 used food diaries and four used a combination of these tools. 209 
Ten studies comprised male only samples and three studies females only. Information on 210 
the numbers of males and females was unavailable in one study (Table 1). 211 
 212 
Study quality and publication bias 213 
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No studies were excluded from the analyses based on quality assessment. Egger’s 214 
regression test identified significant bias (P=0.005), whereas Begg’s test did not (P=0.273). 215 
 216 
FTO and macronutrient intake 217 
The present meta-analysis demonstrated that for each copy of the FTO risk allele, adults had 218 
6.46 kcal/day (95% CI: 10.76, 2.16; P=0.003) lower total energy intake (Figure 2). I2 (95% CI) 219 
were as followings: Caucasian: 19.5% (0, 46); Asian: 38.7% (0, 70); Hispanic: 64.5% (0, 90); 220 
African American: 0% (0, 85); Mixed 0% (-).  These findings remained significant after 221 
adjustment for body weight (-0.158 kcal/kg bodyweight/day [95% CI: -0.298, -0.017]; 222 
P=0.028). Adults carrying the FTO risk allele consumed 0.05% (0.005, 0.067; P=0.028) more 223 
total fat and 0.05% (0.014, 0.082; P=0.006) more protein (Table 2 and Supplementary 224 
Figures 1-3). Following adjustment for body weight the direction of these results changed: 225 
total fat (-0.003, [-0.006, -0.001]; P=0.004), carbohydrates (-0.002 [-0.004, -0.001]; P=0.005) 226 
and protein (-0.002 [-0.003, -0.001]; P=0.001). All results were characterised by low levels of 227 
heterogeneity. No significant associations between FTO genotype and intakes of SFA, MUFA 228 
or PUFA were observed but this finding is based on 6 studies only. 229 
 230 
Meta-regression analysis 231 
Univariate meta-regression analysis indicated that total energy intake (kcals/day) was 62.0 232 
kcal/day lower in Caucasian individuals (95% CI, 106.8, 17.3; P=0.008), 49.6 kcal/day lower 233 
Asian individuals (95% CI, 95.5, 3.7; P=0.035) and 67.5 kcal/day lower in Spanish/Hispanic 234 
individuals (95% CI, 116.4, 18.5; P=0.008) when compared with individuals of mixed 235 
 
 
12 
ethnicities. Protein intake (% energy) was 0.14% (95% CI, 0.082, 0.193; P<0.001) higher in 236 
intervention studies compared with observational studies. No relationships were observed 237 
between intakes of protein (% energy) and age, sex, BMI or sample size, nor between total 238 
energy (kcals/day) or fat, SFA, MUFA, PUFA or carbohydrate (expressed as % total energy) 239 
intake and age, sex, ethnicity, BMI, study design or sample size.  240 
 241 
Sensitivity and subgroup analyses 242 
Stratified analyses (Table 2) indicated that total energy intake was higher in carriers of the 243 
risk allele among Caucasian individuals only, and not in other ethnic groups but this effect 244 
was evaluated by rather few studies (n=16). With each copy of the FTO risk allele, energy 245 
intakes were lower in population-based cohorts and intervention studies only. In contrast, 246 
total energy intakes were higher per copy of the risk allele in case-control and nested case-247 
control studies. The inverse relationship between energy intake and FTO genotype was 248 
significant in overweight individuals only, and not in normal weight or obese individuals. 249 
To estimate potential under-reporting of energy intakes, EI/BMR ratios were calculated 250 
where relevant data were available (n=16). This showed that EI/BMR ratios were not 251 
significantly different across risk alleles (two copies of the risk allele, 1.30±0.31; one copy, 252 
1.33±0.29; no copies, 1.23±0.31; P=0.635).  253 
To assess the influence of extreme values reported for beta coefficients of per allele energy 254 
intake, studies with beta coefficients more than ± 2SD from the mean were excluded (n=3).  255 
Exclusion of these studies resulted in a slightly larger estimate of reduced total energy 256 
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intake (6.6 kcal/day, 95% CI 10.7, 2.4, P=0.002; Supplementary Figure 4) in those carrying 257 
the risk variant of FTO.  258 
Galbraith plots were used as an additional method of detecting heterogeneity between 259 
studies. Of the 56 studies included, these analyses identified one study (NHLBI Family Heart 260 
Study) where the effect size fell outside of the 95% limits (ratio of effect size to standard 261 
error: -2.3; Supplementary Table 2) and was therefore identified as contributing to 262 
heterogeneity45. Exclusion of this study did not change the significance of the results but 263 
lowered the point estimate for reduction in energy intake in those carrying the FTO risk 264 
allele (-5.8 kcal/day, 95% CI:  -10.0, -1.6; P=0.007). I2 (95% CI) were as followings: Caucasian: 265 
13.5% (0, 42); Asian: 38.7% (0, 70); Hispanic: 64.5% (0, 90); African American: 0% (0, 85); 266 
Mixed 0% (-). Finally, small but significant, positive associations were observed between 267 
carriage of the FTO risk allele and BMI as well as with body mass. Individuals with two copies 268 
of the FTO risk allele had a 0.16kg/m2 (95% CI: 0.068, 0.257; P=0.001) higher BMI and 269 
weighed 0.17kg (95% CI: 0.119, 0.227; P<0.001) more than individuals with no copies of the 270 
FTO risk allele (data from 19 studies). 271 
The effect of alcohol intake was assessed across FTO risk allele groups by investigating the 272 
effect of food energy in 13 studies and the effect of percentage total energy intake from 273 
alcohol in 11 studies. Individuals consumed 0.004% (95% CI: -0.032, 0.039) more energy 274 
from alcohol per copy of the FTO risk allele but this effect was not significant (P=0.840; 275 
Table 2). After excluding the contribution of alcohol to total energy intake, i.e. considering 276 
dietary energy intakes only, results showed that with each copy of the FTO risk allele, 277 
individuals consumed 6.4 kcal/day (95% CI: -15.6, 2.7) less energy and, with the wider 278 
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confidence intervals, this effect did not reach significance (P=0.169; Supplementary Figure 279 
5).  280 
 281 
DISCUSSION 282 
Main findings  283 
To our knowledge, this is the first systematic review and meta-analysis to investigate 284 
associations between FTO genotype and macronutrients intake in adults. The present meta-285 
analysis of 56 studies, involving 213 173 individuals, demonstrated that for each copy of the 286 
FTO risk allele, individuals reported significantly lower energy intake (mean 6.5 kcal/day). 287 
Although this difference is small, it is statistically significant and it is in the opposite 288 
direction to that expected from the conventional assumption that the higher body masses in 289 
those carrying the FTO risk variant are due to greater energy intakes. However, the latter 290 
relationship was evident in Caucasians only (there are too few studies in other ethnic groups 291 
at present) and overweight individuals. In addition, Galbraith plots indicated that one study 292 
(FamHS) was identified as an outlier, after removal of this study, the relationship between 293 
FTO genotype and energy intake remained significant (P=0.007). Our analysis also suggested 294 
that FTO genotype is associated with small but statistically significant changes in sources of 295 
dietary energy intake; those carrying the FTO risk allele consumed significantly higher 296 
proportions of dietary energy from fat and protein.  297 
 298 
Comparisons with other studies 299 
Our finding of a small but significantly lower energy intake among FTO carriers is in line with 300 
a recent meta-analysis of individual level data in adults only; Qi et al.18 reported that carriers 301 
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of the FTO risk allele consumed less total energy (6.4 [95% CI -10.1, -2.6] kcal/day) and a 302 
higher protein intake (0.08 [0.06, 0.10]% total energy, P<0.001). Here we have evaluated the 303 
impact of dietary misreporting which, due to self-reporting bias, is a pervasive problem in 304 
most dietary studies and is often more pronounced in overweight and obese individuals46. 305 
Thus, if there was differential misreporting of dietary energy intake according to FTO 306 
genotype e.g. because of the higher prevalence of obesity in those carrying the risk allele, or 307 
for other reasons, such bias could make conclusions about genotypic effects on energy 308 
intake equivocal.  Recent evidence suggests that the FTO risk allele may be associated with 309 
cognitive decline in 45-64 year olds47, particularly with a decline in verbal memory among 310 
Caucasians. These findings would provide a mechanism for potentially greater unintentional 311 
dietary misreporting among FTO allele carriers when assessing dietary intake using recall 312 
methods such as those commonly employed in the studies we reviewed. To date, the 313 
evidence in this area is limited.  Sonestedt et al.48 investigated the role of dietary 314 
misreporting in the relationship between carriage of the FTO allele and energy intake. The 315 
authors used information on physical activity, basal metabolic rates and energy intakes to 316 
predict dietary misreporting. Having excluded both under- and over-reporters of energy 317 
intake, Sonestedt et al.48 found that the inverse relationship between FTO risk allele and 318 
energy intake was no longer significant. Furthermore, Sonestedt et al.48 reported that in 319 
individuals with a BMI >30kg/m2, there was no significant difference between FTO 320 
genotypes in the number of under-reporters. Furthermore, exclusion of under-reporters did 321 
not affect the positive relationship between carriage of the FTO risk allele and intakes of 322 
protein and fat48, all of which are in line with our findings. Previous evidence suggests that 323 
the magnitude of energy under-reported is 20-45%49,50. Our counter-intuitive finding of 324 
lower reported energy intakes among subjects carrying the FTO risk allele is unlikely to be 325 
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explained by systematic under-reporting by carriers of the risk allele of FTO (rs9939609) 326 
because estimates of EI/BMRs were very similar for those carrying 0, 1 and 2 copies of the 327 
FTO risk allele. However, in the absence of reliable estimates of energy expenditure or of 328 
individual level data for age, sex and body mass (required for prediction of individual dietary 329 
energy needs), it is difficult to exclude the possibility that the small differences in energy 330 
intake observed in the studies considered in our systematic review are due to energy under-331 
reporting by carriers of FTO risk allele. Alternatively, as shown in overfeeding studies51, the 332 
FTO risk variant may lead to a higher energy efficiency in weight gain per kcal intake, which 333 
is a mechanism that requires further investigation.  334 
For many adults, alcohol contributes substantially (3 – 9%) to total energy intake and may 335 
drive higher food intake52. Thus, genetic differences in actual or reported alcohol intake 336 
could confound apparent differences in energy and macronutrients intake according to FTO 337 
genotype. Our meta-analysis was based primarily on reported total energy intakes rather 338 
than energy intakes from food only. There may be a positive relationship between the FTO 339 
genotype and alcohol intake53, although this finding is not consistent54. Previous evidence 340 
syntheses have not investigated the potential impact of alcohol intake on the relationship 341 
between FTO genotype and energy intake18. Where relevant data were available, we 342 
assessed the relationship between intake of food energy and FTO genotype, thereby 343 
excluding any influence of alcohol intakes on the analyses. Moreover, where relevant data 344 
were available, we estimated the percentage energy intake from alcohol to investigate 345 
possible differences between FTO genotypes. These exploratory analyses, based on a 346 
limited number of relevant studies, suggest that the lower intake of energy per copy of FTO 347 
variant was not affected by alcohol intake and that alcohol intake is not significantly 348 
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different between FTO risk alleles. However, as with energy intake, under-reporting of 349 
alcohol intake, is a pervasive issue55. 350 
Although animal studies suggest that FTO expression may affect energy homeostasis via 351 
changes in food intake9,56, our findings provide little support for the hypothesis that 352 
increased energy intake mediates the obesogenic effects of the FTO risk allele in humans. 353 
Due to limited data on physical activity in these studies, we were unable to assess the effect 354 
of FTO on energy expenditure. Nonetheless, research using doubly labelled water suggests 355 
that there is no difference in energy expenditure between FTO risk variants after adjustment 356 
for body weight14. Furthermore, there is no evidence for a direct connection between 357 
obesity-associated variants and FTO expression57,58. Smemo et al.59 demonstrated recently 358 
that these obesogenic SNPs within FTO may be regulated by the homobox gene IRX3, 359 
referred to as the “functional obesity gene”. The reduction in body weight of 25-30% in 360 
IRX3-deficient mice was more pronounced when animals were subjected to a high-fat diet, 361 
thereby supporting the potential for FTO to influence energy efficiency, and suggesting that 362 
IRX3 may be the pivotal link between FTO, macronutrient intake and obesity59. Furthermore, 363 
an additional SNP in the first intron of FTO, RPGRIP1L, has been proposed as partly or 364 
exclusively responsible for the obesity susceptibility signal at the FTO locus in mice60. 365 
 366 
Strengths and limitations 367 
The strengths of this study include application of a rigorous methodology in the systematic 368 
review of the literature and the availability of data from a large population of 213 173 369 
individuals. In addition, we examined the potential confounding effect of alcohol intake (a 370 
significant source of energy for many adults) on the relationship between FTO genotype and 371 
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energy intake. A limitation of the present study was that sensitivity analyses using intakes of 372 
food energy and data on body weight were possible for less than half of the studies 373 
included. This limited our ability to ascertain whether our findings were attenuated 374 
following these adjustments. Furthermore, all studies utilised self-report methods for 375 
quantifying dietary intakes. The well-recognised limitations of dietary self-reporting tools 376 
may also be amplified when focusing on overweight and obese subjects. Progress in the 377 
development of objective biomarkers of dietary intake may overcome some of these 378 
limitations61. Finally, the findings of this review are based largely on studies of Caucasians, 379 
thus highlighting the lack of studies that have assessed associations between FTO genotype 380 
and dietary intake among non-Caucasians. 381 
 382 
Implications of the findings and future research  383 
Despite observing significant differences in energy and nutrient intakes between FTO 384 
variants, these seem to be too small to play an important role in the greater obesity 385 
prevalence commonly seen among FTO carriers. In addition, given the growing interest in 386 
the development of personalised advice based on the genetic makeup of individuals, the 387 
findings from this study indicate that there is limited justification for providing differential 388 
advice for total energy and macronutrients intakes according to FTO genotype as a means of 389 
combatting the obesity epidemic. 390 
This review indicates there is a paucity of studies evaluating the association of FTO and 391 
dietary intakes among non-Caucasian ethnic groups. This situation is expected to change 392 
given the great interest on the development of personalised lifestyle advice as an approach 393 
to addressing the obesity epidemic. Dietary misreporting, a ubiquitous problem in most 394 
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dietary studies, was identified in the reviewed studies. Assessment of dietary intake is often 395 
considered a straightforward task, receiving little attention during the design of studies, but 396 
it is now clear that inaccuracies in the measurement of dietary intake may lead to spurious 397 
associations between diet and health. Therefore, future research should aim to develop and 398 
use more accurate methods of assessing dietary intake and energy balance61.  399 
Recent research on dietary patterns suggests a relationship between greater consumption 400 
of fried food and FTO genotype62. These results are in line with our findings of small but 401 
significantly greater intakes of dietary fat and protein by FTO carriers, which may be 402 
attributable to the consumption of high-fat, processed meat products. However, given the 403 
findings of energy under-reporting across all studies and FTO groups, it is uncertain whether 404 
there is selective under-reporting of dietary fat intake63. With the growing emphasis on 405 
whole foods and dietary patterns in dietary recommendations, there may be future scope 406 
for genetics-based dietary advice targeting dietary patterns.  407 
Finally, as summarised in Table S3, the present systematic review and meta-analysis has 408 
highlighted a number of areas which should be improved in future studies. When reporting 409 
dietary intakes, total energy intakes (kcal/day) and macronutrients intakes should be 410 
reported for each copy of the risk allele. Critically, if dietary intakes are self-reported, 411 
estimates of dietary misreporting based on the ratio of BMR to energy intake should be 412 
reported per copy of the risk allele. Without this information it is not possible to assess 413 
objectively the role of dietary intake in mediating the effects of genetic risk of obesity. 414 
Finally, it is recommended that studies provide per risk allele data on physical activity 415 
(quantified as Metabolic Equivalents of Task (METs)). This information, together with 416 
quantitative information on dietary intakes and estimated BMRs, would help to provide 417 
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insight into which aspect(s) of the energy balance equation is influenced by the genetic 418 
variant. 419 
 420 
Conclusions 421 
Our systematic review and meta-analysis indicates a weak inverse association between the 422 
FTO risk allele and energy intake in adults, which is consistent with recent findings from a 423 
meta-analysis of individual level data18. Our findings also suggest a role of FTO in altering 424 
the proportions of dietary energy consumed as fat and protein. With the lack of appropriate 425 
individual data, we could not discount the possibility that dietary intake misreporting is 426 
responsible for these apparent effects. Furthermore, with limited data on energy 427 
expenditure via physical activity, we were unable to ascertain the effects of the FTO risk 428 
allele on the energy balance equation. Future intervention and mechanistic studies in 429 
humans, where dietary intakes are recorded objectively and the mechanisms of the action 430 
of FTO and its associated genes are investigated, are required to better understand the 431 
putative relationship between FTO and macronutrients intake.  432 
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Fig 1. Study selection flow diagram based on the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analyses) statement 
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Fig 2. Forest plot of associations between FTO rs9939609 genotype or a proxy and total energy 
intake in a random effects meta-analysis of 213 173 adults. Studies are stratified by ethnic 
background and sorted by sample size (smallest to largest). The effect size (ES) represents the beta 
coefficient for the difference in energy intake (kcal/day) per minor allele of FTO rs9939609 or a 
proxy.  
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Table 1. Characteristics of the studies included, by age group 
Reference Study name 
Number of participants 
SNP Study design Region Ethnicity 
Age (years; 
SD) 
BMI (kg/m
2
) 
All Men Women 
Baik et al. 
30
 KoGES 4590 2241 2349 rs9939609 Case-control Asia Asian 51.96 (8.70) 23.71 (2.82) 
Bauer et al. 
31
  - 1600 0 1600 rs1121980 Population-based cohort Europe Caucasian 57.20 (6.10) 25.80 (4.00) 
Celis-Morales et al.
 32 
GENADIO 437 206 231 rs3751812 Cross sectional study South America Spanish/Hispanic 37.15 (12.96) 27.94 (3.75) 
Corella et al. 
33 
BPRHS 1069 507 562 rs9939609 Population-based cohort North America Caucasian 48.84 (16.17) 28.26 (5.62) 
Corella et al. 
33 
GOLDN 7052 3462 4297 rs9939609 Intervention study Europe Spanish/Hispanic 66.98 (6.23) 29.94 (3.90) 
Dougkas et al. 
34 
- 40 40 0 rs9939609 Intervention study Europe Caucasian 32.10 (9.10) 26.80 (1.60) 
Franks et al. 
35 
DPP 3451 1150 2301 rs9939609 Intervention study North America Caucasian 50.80 (10.59) 28.00 (6.66) 
Galbete et al. 
36 
SUN 967 667 290 rs9939609 Population-based cohort Europe Spanish/Hispanic 68.90 (6.10) 25.78 (3.20) 
Huang et al. 
17 
POUNDS LOST 737 286 451 rs9939609 Intervention study North America Caucasian 50.97 (9.22) 32.68 (3.85) 
Hubacek et al. 
37 
HAPIEE 6024 2780 3244 rs17817449 Population-based cohort Czech Republic Caucasian 58.10 (6.90) 28.20 (4.60) 
Karasawa et al. 
38 
Takahata 1473 633 840 rs9939609 Cross sectional study Japan Asian 63.00 (10.20) 23.50 (3.20) 
Lappalainen et al. 
39 
FDPS 479 160 319 rs9939609 Intervention study Europe Caucasian 55.20 (7.08) 31.20 (4.46) 
Lear et al. 
40 
M-CHAT 702 348 354 rs9939609 Cross sectional study Canada Mixed 47.43 (8.83) 27.54 (4.87) 
Lee et al. 
41 
GPC 8477 - - rs9939609 Population-based cohort Asia Asian 52.22 (8.92) 24.60 (3.34) 
Livingstone et al.* Food4Me 1472 611 861 rs9939609 Intervention study Europe Caucasian 39.9 0(13.00) 25.50 (4.88) 
Matsuo et al. 
42 
- 204 0 204 rs9939609 Intervention study Asia Asian 51.90 (8.88) 28.45 (3.02) 
McCaffery et al. 
43 
Look AHEAD 2069 909 1160 rs9939609 Intervention study North America Mixed 57.55 (7.40) 36.30 (6.08) 
Phillips et al.
 44 
SU.VI.MAX 1753 180 120 rs9939609 Nested case-control Europe Caucasian 51.64 (5.41) 25.32 (5.41) 
Speakman et al. 
16 
- 107 43 107 rs9939609 Community-based cohort Europe Caucasian 43.73 (11.29) 26.49 (6.19) 
Qi et al. 
18
 ADIGEN 393 393 0 rs9939609 Case-control Europe Caucasian 43.86 (5.89) 29.39 (4.02) 
Qi et al. 
18 
ARIC 12212 5452 6760 rs9939609 Population-based cohort North America Mixed 54.06 (5.73) 27.65 (5.01) 
Qi et al.
 18 CHS 3731 1445 2286 rs9939609 Community-based cohort North America Caucasian 72.55 (5.35) 26.54 (4.50) 
Qi et al. 
18 CLHNS 1612 0 1612 rs9939609 Cohort of women Asia Asian 48.40 (6.00) 24.50 (4.30) 
Qi et al. 
18 CoLaus 2928 1327 1601 rs9939609 Population-based cohort Europe Caucasian 53.15 (10.59) 25.48 (4.24) 
Qi et al. 
18 DILGOM 611 292 319 rs9939609 Cross-sectional study Europe Caucasian 53.17 (13.37) 26.74 (4.54) 
Qi et al. 
18 EPIC_Norfolk 19105 9483 9622 rs9939609 Population-based cohort Europe Caucasian 59.40 (9.30) 26.30 (3.70) 
Qi et al. 
18 FamHS 3593 1698 1895 rs9939609 Family study North America Caucasian 52.26 (13.64) 27.74 (5.44) 
Qi et al. 
18 Fenland 3668 1678 1990 rs9939609 Population-based cohort Europe Caucasian 46.10 (7.17) 26.96 (4.88) 
Qi et al. 
18 FHS 3064 1630 1434 rs9939609 Family study North America Caucasian 54.70 (9.80) 27.40 (4.90) 
Qi et al. 
18 GEMINAKAR 1190 576 614 rs9939609 Twin study Europe Caucasian 38.05 (11.44) 24.39 (3.46) 
Qi et al. 
18 Generation R 2548 0 3548 rs9939609 Population-based cohort Europe Caucasian 31.40 (4.30) 23.20 (4.00) 
Qi et al. 
18 GLACIER 15728 6263 9465 rs9939609 Population-based cohort Europe Caucasian 52.08 (8.70) 25.90 (4.10) 
Qi et al. 
18 HBCS 1334 667 894 rs9939609 Birth cohort Europe Caucasian 61.50 (2.85) 27.70 (4.70) 
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Table 1. Characteristics of the studies included, by age group continued 
Reference Study name 
Number of participants 
SNP Study design Region Ethnicity 
Age (years; 
SD) 
BMI (kg/m
2
) 
All Men Women 
Qi et al. 
18                             
 HCS 2105 1174 931 rs9939609 Cross sectional study Europe Caucasian 66.21 (2.81) 27.32 (4.28) 
Qi et al. 
18
 Health 2000 3044 1290 1754 rs9939609 Cross sectional study Europe Caucasian 53.59 (16.38) 26.61 (4.68) 
Qi et al. 
18
 Health ABC 2392 1168 1224 rs9939609 Population-based cohort North America Mixed 74.64 (2.88) 27.23 (4.52) 
Qi et al. 
18
 HERITAGE 497 240 257 rs9939609 Family study North America Caucasian 35.80 (14.6) 25.80 (5.00) 
Qi et al. 
18
 HPFS 4546 4564 0 rs9939609 Nested case-control North America Caucasian 55.27 (8.69) 25.83 (3.23) 
Qi et al. 
18
 InCHIANTI 1122 504 618 rs9939609 Population-based cohort Europe Caucasian 67.64 (0.65) 27.17 (0.20) 
Qi et al. 
18
 INTER99 5561 2843 5561 rs9939609 Population-based cohort Europe Caucasian 46.24 (7.85) 26.29 (4.56) 
Qi et al. 
18
 MDC 22692 9108 13584 rs9939609 Population-based cohort Europe Caucasian 58.34 (7.66) 25.72 (3.88) 
Qi et al. 
18
 MESA 3621 1726 1895 rs9939609 Population-based cohort North America Mixed 62.64 (10.18) 28.56 (5.15) 
Qi et al. 
18
 MRC Ely 1567 732 835 rs9939609 Population-based cohort Europe Caucasian 61.18 (9.25) 27.35 (4.75) 
Qi et al. 
18
 NHAPC 3145 1363 1782 rs9939609 Population-based cohort Europe Caucasian 58.67 (6.01) 24.44 (3.58) 
Qi et al. 
18
 NHS 7557 0 7557 rs9939609 Nested case-control North America Caucasian 54.00 (6.65) 25.85 (4.95) 
Qi et al. 
18
 QFS 773 337 436 rs9939609 Family study North America Caucasian 41.02 (14.86) 27.63 (7.63) 
Qi et al. 
18
 ROTTERDAM 4574 1894 2680 rs9939609 Population-based cohort Europe Caucasian 67.57 (7.67) 26.33 (3.55) 
Qi et al. 
18
 SBCGWAS 2551 0 2551 rs9939609 Case-control Asia Asian 49.90 (8.50) 23.90 (3.40) 
Qi et al. 
18
 SDGWAS 886 0 886 rs9939609 Case-control Asia Asian 51.30 (6.30) 26.70 (3.70) 
Qi et al. 
18
 SECGS 826 0 826 rs9939609 Case-control Asia Asian 54.80 (8.70) 25.70 (4.10) 
Qi et al. 
18
 SP2 2143 991 1152 rs9939609 Case-control Asia Asian 48.17 (11.10) 19.36 (3.11) 
Qi et al. 
18
 SWHS 2308 0 2308 rs9939609 Case-control Asia Asian 49.60 (8.50) 23.40 (3.30) 
Qi et al. 
18
 THISEAS 733 396 337 rs9939609 Case-control Europe Caucasian 57.13 (12.75) 28.35 (4.53) 
Qi et al. 
18 WGHS 22296 0 22296 rs9939609 Cohort of women North America Caucasian 54.20 (7.10) 25.90 (4.90) 
Qi et al. 
18 YangPyeung 2188 834 1354 rs9939609 Population-based cohort Asia Asian 57.62 (12.60) 24.48 (3.25) 
Qi et al. 
18 YFS 1626 709 917 rs9939609 Population-based cohort Europe Caucasian 37.71 (5.00) 25.77 (4.45) 
*KM Livingstone, CM Celis & JC Mathers on behalf of Food4Me – unpublished data
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Table 2. Associations between energy and macronutrients intakes and FTO rs9939609 genotype 
(or a proxy) in adults 
Variable Beta-coeff (95% CI)
a
 P-value I
2
 (95% CI) 
Dietary intake (% energy)    
Total fat (n=51) 0.045 (0.005, 0.066) 0.028 22.2 (0 to 45) 
Saturated fat (n=5) 0.057 (-0.290, 0.144) 0.194 58.7 (0 to 85) 
Monounsaturated fat (n=6) -0.018 (-0.097, 0.061) 0.661 66.6 (20 to 86) 
Polyunsaturated fat (n=5) -0.026 (-0.070, 0.019) 0.259 69.9 (23 to 88) 
Carbohydrates (n=51) -0.013 (-0.046, 0.021) 0.426 34.1 (7 to 53) 
Protein (n=49) 0.048 (0.014, 0.082) 0.006 55.3 (38 to 68) 
Alcohol (n=11) 0.004 (-0.032, 0.039) 0.840 62.1 (27 to 80) 
    
Energy intake (kcal/day) by study design    
Case-control/ nested case-control (n=11) 0.263 (-0.020, 0.545) 0.068 0.00 (0 to 60) 
Community/population-based cohort (n=24) -6.647 (-10.761, -2.532) 0.002 0.00 (0 to 45) 
Family/twin or birth cohort (n=7) -13.346 (-37.046, 10.355) 0.270 23.8 (0 to 66) 
Cross sectional study (n=6) 6.563 (-29.557, 42.684) 0.722 50.2 (0 to 80) 
Intervention study (n=7) -19.811 (-34.611, -5.011) 0.009 33.1 (0 to 72) 
    
Energy intake (kcal/day) by dietary collection method 
FFQ (n= 40) -7.952 (-12.765, -3.138) 0.318 8.50 (0 to 37) 
Food diary (n=7) 13.093 (-25.605, 51.791) 0.020 60.1 (8 to 83) 
Dietary recall (n=4) 0.321 (-8.065, 8.707) 0.032 66.0 (0 to 88) 
Other (n=4) -8.442 (-22.181, 5.297) 0.377 3.20 (0 to 85) 
    
Energy intake (kcal/day) by BMI    
Normal  (n=8) 7.072 (-8.369, 22.512) 0.369 0.00 (0  to 68) 
Overweight (n=44) -6.824 (-11.325, -2.323) 0.003 37.3 (9 to 57) 
Obese (n=3) -11.116 (-67.416, 45.182) 0.699 73.0 (9 to 92) 
    
Dietary intake per kg body weight    
Total energy intake (kcal/kgbw/day; n=19) -0.158 (-0.298, -0.017) 0.028 64.5 (42 to 78) 
Total fat (% energy; n=15) -0.003 (-0.006, -0.001) 0.004 67.1 (44 to 81) 
Saturated fat (% energy; n=7) -0.001 (-0.002, 0.000) 0.134 58.9 (0 to 83) 
Monounsaturated fat (% energy; n=6) -0.003 (-0.005, 0.000) 0.071 63.8 (12 to 85) 
Polyunsaturated fat (% energy; n=6) -0.001 (-0.003, 0.000) 0.060 71.8 (35 to 88) 
Carbohydrates (% energy; n=15) -0.002 (-0.004, -0.001) 0.005 68.0 (45 to 81) 
Protein (% energy; n=14) -0.002 (-0.003, -0.001) 0.001 56.7 (21 to 76) 
Alcohol (% energy; n=10) -0.000 (-0.000, 0.000) 0.630 70.0 (42 to 84) 
 
Energy intake (kcal/day) per kg body weight by Ethnicity 
Caucasian (n=10) -0.379 (-0.648, -0.110) 0.006 61.0 (22 to 80) 
Asian (n=4) -0.796 (-1.719, 0.126) 0.049 61.9 (0 to 87) 
Spanish/Hispanic (n=3) -0.268 (-1.164, 0.629) 0.012 77.2 (26 to 93) 
Mixed (n=2) 0.189 (0.038, 0.341) 0.922 64.5 (-) 
a
Beta coefficients represent the difference in dietary intake per risk allele of FTO rs9939609 or a proxy. 
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 Fig S1. Forest plot of associations between FTO rs9939609 genotype or a proxy and fat intake in a 
random effects meta-analysis of 213 173 adults. Studies are sorted by sample size (smallest to 
largest). The effect size (ES) represents the beta coefficient for the difference in fat intake (% energy) 
per minor allele of FTO rs9939609 or a proxy. 
 
Lower Fat intake                Higher Fat Intake 
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 Fig S2. Forest plot of associations between FTO rs9939609 genotype or a proxy and carbohydrate 
intake in a random effects meta-analysis of 213 173 adults. Studies are sorted by sample size 
(smallest to largest). The effect size (ES) represents the beta coefficient for the difference in 
carbohydrate intake (% energy) per minor allele of FTO rs9939609 or a proxy.
Lower Carbohydrate intake                Higher Carbohydrate Intake 
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Fig S3. Forest plot of associations between FTO rs9939609 genotype or a proxy and protein intake in 
a random effects meta-analysis of 213 173 adults. Studies are sorted by sample size (smallest to 
largest). The effect size (ES) represents the beta coefficient for the difference in protein intake (% 
energy) per minor allele of FTO rs9939609 or a proxy. 
 
Lower Protein intake                             Higher Protein Intake 
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Fig S4. Forest plot of associations between FTO rs9939609 genotype (or a proxy) and total energy 
intake (kcal/day) in a random effects meta-analysis of 213 173 adults where studies with beta 
coefficients more than 2SD from the mean were excluded. Studies are sorted by sample size 
(smallest to largest). The effect size (ES) represents the beta coefficient for the difference in energy 
intake (kcal/day) per minor allele of FTO rs9939609 or a proxy.  
Lower Energy intake               Higher Energy Intake 
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Fig S5. Forest plot of associations between FTO rs9939609 genotype (or a proxy) and food energy 
intake (kcal/day) in a random effects meta-analysis of 213 173 adults. Studies are sorted by sample 
size (smallest to largest). The effect size (ES) represents the beta coefficient for the difference in 
energy intake (kcal/day) per minor allele of FTO rs9939609 or a proxy.
Lower Energy intake                   Higher Energy Intake 
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Table S1. Energy intakes (kcal/day) and ratios of basal metabolic rate (BMR) to energy intake per copy of FTO risk allele 
 
Reference  Study Name Sample size Energy intake (kcal/day) Ratio of BMR to energy intake** 
Two copies One copy  No copies  Two copies One copy  No copies  Two copies One copy  No copies  
Baik et al. 
30 
KoGES 72 956 3562 1920.1 (482.6) 1925.4 (736.0) 1919.6 (821.9) 1.40 1.39 1.32 
Bauer et al. 
31 
- 1600 306 737 1771.3 (570.4) 1796.4 (565.5) 1817.7 (583.1) 1.27 1.31 1.16 
Celis-Morales et al. 
32 
GENADIO 203 167 67 2752.5 (887.2) 2632.6 (772.6) 2638.3 (890.8) 1.78 1.75 1.68 
Corella et al. 
33 
BPRHS 188 556 325 1951.4 (785.8) 2058.9 (869.4) 2094.7 (864.6) - - - 
Corella et al. 
33 
GOLDN 1289 3434 2329 2250.8 (593.9) 2277.3 (606.4) 2288.2 (616.1) 1.53 1.58 1.59 
Dougkas et al. 
34 
- 12 17 11 841.8 (303.1) 1052.6 (392.2) 911.8 (262.2) - - - 
Franks et al. 
35 
DPP 593 1623 1235 2079.3 (920.6) 2131.4 (1032.5) 2153.4 (1103.7) 1.18 1.24 1.12 
Galbete et al. 
36 
SUN 165 466 336 2352.0 (950.1) 2396.0 (830.1) 2412.0 (1038.0) 1.58 1.65 1.65 
Huang et al. 
17 
POUNDS LOST 150 360 227 1933.0 (575.0) 1960.0 (555.0) 1933.0 (563.0) 1.12 1.14 1.01 
Hubacek et al. 
37 
HAPIEE 1157 2886 1981 2044.0 (891.0) 2036.0 (876.0) 2055.0 (766.0) 1.27 1.28 1.20 
Karasawa et al. 
38 
Takahata 67 456 950 2109.0 (564.0) 2270.0 (665.0) 2236.0 (696.0) - - - 
Lappalainen et al. 
39 
FDPS 88 230 161 1716.0 (479.0) 1789.9 (542.1) 1761.0 (496.9) 1.05 1.10 0.98 
Lear et al. 
40 
M-CHAT 702 56 260 2039.6 (602.0) 1875.5 (553.1) 1918.7 (619.1) 1.29 1.18 1.15 
Lee et al. 
42 
GPC 143 1844 6490 1792.7 (507.3) 1894.5 (731.6) 1884.4 (673.9) - - - 
Livingstone et al.*  Food4Me 264 739 469 2519.7 (874.2) 2529.4 (917.0) 2553.4 (957.5) 1.65 1.66 1.55 
Matsuo et al. 
42 
- 15 75 114 1740.0 (454.0) 1838.0 (357.0) 1884.0 (349.0) 1.23 1.36 1.20 
McCaffery et al. 
43 
Look AHEAD 2069 432 989 2038.0 (921.7) 2004.8 (832.7) 1943.3 (910.2) 1.08 1.08 0.96 
Phillips et al. 
44 
SU.VI.MAX 307 850 596 2263.3 (49.0) 2292.0 (53.1) 2251.4 (35.1) 1.46 1.48 1.41 
Speakman et al. 
13 
- 20 57 30 2114.7 (120.9) 2253.9 (97.3) 1994.1 (84.3) 1.44 1.50 1.23 
*KM Livingstone, CM Celis & JC Mathers on behalf of Food4Me – unpublished data, ** Basal metabolic rates (BMR) were calculated using Oxford equations
28
 and ratios 
were estimated by dividing reported energy intakes by BMRs 
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Table S2 Galbraith plot values sorted by decreasing beta/SE. Detection of studies acting as sources of 
heterogeneity for the associations between FTO rs9939609 genotype (or a proxy) and total energy 
intake (kcal/day). Study 55 is an outlier as the effect size lies outside the 95% confidence interval for 
the pooled effect. 
Reference Number on plot Study reference beta/SE 1/SE 
Phillips et al (2012) 1 SU.VI.MAX 1.73 0.29 
McCaffery et al (2012) 2 Look AHEAD 1.73 0.04 
Baik et al (2012) 3 KoGES 1.73 6.93 
Celis-Morales et al (2014) 4 GENADIO 1.73 0.03 
Lear et al (2011) 5 M-CHAT 1.73 0.03 
Speakman et al (2008) 6 RCT 1.73 0.03 
Qi et al (2014) 7 SECGS  1.55 0.03 
Qi et al (2014) 8 SWHS  1.29 0.05 
Qi et al (2014) 9 SBCGWAS  1.27 0.05 
Qi et al (2014) 10 CLHNS 0.89 0.05 
Qi et al (2014) 11 YangPyeung 0.86 0.03 
Qi et al (2014) 12A CHS_AA 0.78 0.01 
Qi et al (2014) 13 WGHS  0.65 0.20 
Qi et al (2014) 14 NHAPC  0.48 0.03 
Qi et al (2014) 15 DILGOM 0.44 0.02 
Qi et al (2014) 16 HBCS 0.42 0.03 
Qi et al (2014) 17 QFS 0.27 0.02 
Qi et al (2014) 18 NHS 0.24 0.08 
Qi et al (2014) 19 SDGWAS  0.22 0.03 
Qi et al (2014) 20 INTER99 0.19 0.05 
Qi et al (2014) 21A Health ABC_AA 0.06 0.02 
Qi et al (2014) 22 GEMINAKAR  0.01 0.03 
Qi et al (2014) 23 Health 2000 -0.02 0.04 
Qi et al (2014) 24A ARIC_AA -0.05 0.05 
Qi et al (2014) 25 ADIGEN -0.07 0.02 
Qi et al (2014) 26 Fenland -0.10 0.03 
Qi et al (2014) 27A MESA_AA -0.20 0.02 
Qi et al (2014) 28 SP2 -0.36 0.01 
Qi et al (2014) 29 YFS -0.38 0.04 
Qi et al (2014) 30 MRC Ely  -0.57 0.03 
Qi et al (2014) 12B CHS_W -0.62 0.05 
Qi et al (2014) 21B Health ABC_W -0.65 0.03 
Qi et al (2014) 31 THISEAS -0.80 0.01 
Qi et al (2014) 32 CoLaus -0.88 0.06 
Qi et al (2014) 33 HPFS -0.88 0.07 
Qi et al (2014) 34 HCS -0.95 0.05 
Qi et al (2014) 35 GLACIER  -0.96 0.10 
Qi et al (2014) 36 MDC -0.98 0.15 
Qi et al (2014) 37 ROTTERDAM  -1.10 0.07 
Qi et al (2014) 38 FHS  -1.17 0.06 
Qi et al (2014) 39 Generation R  -1.31 0.07 
Qi et al (2014) 27B MESA_W -1.41 0.03 
Qi et al (2014) 40 HERITAGE  -1.45 0.02 
Qi et al (2014) 41 InCHIANTI  -1.48 0.03 
Qi et al (2014) 42 EPIC_Norfolk -1.62 0.12 
Qi et al (2014) 24B ARIC_W -1.62 0.08 
Lappalainen et al (2012) 43 FDPS -1.73 0.08 
Livingstone et al (2014) 44 Food4Me -1.73 0.10 
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Franks et al (2008) 45 DPP -1.73 0.05 
Bauer et al (2009) 46 RCT -1.73 0.07 
Dougkas et al (2013) 47 RCT -1.73 0.05 
Galbete et al (2013) 48 SUN -1.73 0.06 
Hubacek et al (2011) 49 HAPIEE -1.73 0.31 
Matsuo et al (2012) 50 RCT -1.73 0.02 
Corella et al (2011) 51 GOLDN -1.73 0.02 
Karasawa et al (2010) 52 Takahata -1.73 0.03 
Lee et al (2010) 53 GPC -1.73 0.04 
Corella et al (2012) 54 PREDIMED -1.73 0.09 
Qi et al (2014) 55 FamHS -2.34 0.05 
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Table S3. Recommendations for future studies into genotype/dietary relationships 
Topic Recommendation 
Per risk allele breakdown Provide data stratified by each copy of the risk allele. These data should 
include demographic characteristics (sample size, age, sex, height, weight, 
BMI), dietary intakes (total energy and macronutrients intake and degree of 
misreporting) and lifestyle variables (physical activity)  
 
Dietary intakes Report total energy intakes (kcal/day or KJ/day) and percentage energy 
intakes from total fat, carbohydrates, protein and alcohol. If available, the 
inclusion of the percentage energy intakes from saturated, mono- and 
polyunsaturated fat and sugar is encouraged. 
 
Dietary misreporting If dietary intakes are self-reported, provide individual-level basal metabolic 
rates (BMR) and the ratios of BMR to total energy intake, as an estimation of 
dietary under-reporting. 
 
Physical activity Report levels of physical activity in MET (metabolic equivalent) 
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Table S3. PRISMA checklist 
 
 
Section/topic  # Checklist item  
Reported 
on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  1 
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, 
participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of 
key findings; systematic review registration number.  
4 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  6 
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, 
outcomes, and study design (PICOS).  
7 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration 
information including registration number.  
7 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, 
publication status) used as criteria for eligibility, giving rationale.  
7-8 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional 
studies) in the search and date last searched.  
7-8 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.  7-8 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in 
the meta-analysis).  
7-8 
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for 
obtaining and confirming data from investigators.  
8-9 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
8-9 
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Table S3. PRISMA checklist continued 
  
Section/topic  # Checklist item  Reported on page #  
Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
9 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  9 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency 
(e.g., I
2
) for each meta-analysis.  
9 
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
9 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating 
which were pre-specified.  
10 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at 
each stage, ideally with a flow diagram.  
10-11 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and 
provide the citations.  
11 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  11-12 
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
12-15 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Tables/Figures/Suppl 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  12-15 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  12-15 
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Table S3. PRISMA checklist continued 
 
Section/topic  # Checklist item  
Reported 
on page #  
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key 
groups (e.g., healthcare providers, users, and policy makers).  
15-19 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified 
research, reporting bias).  
19 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  20-21 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the 
systematic review.  
2 
 
 
 
 
